Intra-Cellular Therapies (ITCI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ITCI Stock Forecast

Intra-Cellular Therapies stock forecast is as follows: an average price target of $93.33 (represents a 11.84% upside from ITCI’s last price of $83.45) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

ITCI Price Target

The average price target for Intra-Cellular Therapies (ITCI) is $93.33 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $106.00 to $79.00. This represents a potential 11.84% upside from ITCI's last price of $83.45.

ITCI Analyst Ratings

Buy

According to 9 Wall Street analysts, Intra-Cellular Therapies's rating consensus is 'Buy'. The analyst rating breakdown for ITCI stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Intra-Cellular Therapies Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 30, 2024	Corinne Jenkins	Goldman Sachs	$79.00	$85.47	-7.57%	-5.33%
Sep 05, 2024	David Amsellem	Piper Sandler	$92.00	$72.42	27.04%	10.25%
Aug 08, 2024	Brian Abrahams	RBC Capital	$106.00	$73.63	43.96%	27.02%
Aug 07, 2024	Corinne Jenkins	Goldman Sachs	$74.00	$73.63	0.50%	-11.32%
Jul 22, 2024	Ami Fadia	Needham	$100.00	$74.86	33.58%	19.83%
Jun 25, 2024	Ashwani Verma	UBS	$83.00	$72.42	14.61%	-0.54%
Jun 20, 2024	Graig Suvannavejh	Mizuho Securities	$100.00	$76.06	31.48%	19.83%
Jun 18, 2024	Brian Abrahams	RBC Capital	$103.00	$75.48	36.46%	23.43%
May 07, 2024	Brian Abrahams	RBC Capital	$96.00	$71.21	34.81%	15.04%
May 07, 2024	Andrew Tsai	Jefferies	$105.00	$70.08	49.84%	25.82%
Apr 23, 2024	Sumant Kulkarni	Canaccord Genuity	$107.00	$74.54	43.55%	28.22%
Apr 17, 2024	Joel Beatty	Robert W. Baird	$103.00	$79.84	29.01%	23.43%
Apr 05, 2024	Ami Fadia	Needham	$82.00	$67.21	22.01%	-1.74%
Jun 13, 2022	Ashwani Verma	UBS	$75.00	$53.07	41.32%	-10.13%
Apr 22, 2022		Piper Sandler	$59.00	$55.75	5.83%	-29.30%
Apr 21, 2022		Leerink Partners	$70.00	$59.98	16.71%	-16.12%
Feb 17, 2022	Corinne Jenkins	Goldman Sachs	$64.00	$57.49	11.32%	-23.31%

The latest Intra-Cellular Therapies stock forecast, released on Oct 30, 2024 by Corinne Jenkins from Goldman Sachs, set a price target of $79.00, which represents a -7.57% decrease from the stock price at the time of the forecast ($85.47), and a -5.33% decrease from ITCI last price ($83.45).

Intra-Cellular Therapies Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	13
Avg Price Target	-	$79.00	$94.62
Last Closing Price	$83.45	$83.45	$83.45
Upside/Downside	-100.00%	-5.33%	13.39%

In the current month, the average price target of Intra-Cellular Therapies stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Intra-Cellular Therapies's last price of $83.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 31, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Oct 30, 2024	Goldman Sachs	Neutral	Neutral	Hold
Oct 11, 2024	Morgan Stanley	Overweight	Overweight	Hold
Oct 04, 2024	RBC Capital	Underperform	Underperform	Hold
Oct 04, 2024	UBS	Buy	Buy	Hold
Sep 06, 2024	RBC Capital	Underperform	Underperform	Hold
Sep 06, 2024	UBS	Buy	Buy	Hold
Sep 05, 2024	Piper Sandler		Overweight	Upgrade
Aug 08, 2024	RBC Capital	Outperform	Outperform	Hold
Aug 07, 2024	Goldman Sachs	Neutral	Neutral	Hold
Jul 22, 2024	RBC Capital	Underperform	Underperform	Hold
Jul 22, 2024	UBS	Buy	Buy	Hold
Jul 22, 2024	Needham	Buy	Buy	Hold
Jun 25, 2024	UBS	Buy	Neutral	Downgrade
Jun 25, 2024	RBC Capital	Outperform	Outperform	Hold
Jun 12, 2024	RBC Capital	Buy	Buy	Hold
Jun 12, 2024	Needham	Underperform	Underperform	Hold
May 31, 2024	RBC Capital	Outperform	Outperform	Hold
May 08, 2024	RBC Capital	Buy	Buy	Hold
May 08, 2024	Needham	Underperform	Underperform	Hold
May 07, 2024	RBC Capital	Outperform	Outperform	Hold
May 07, 2024	Jefferies	Buy	Buy	Hold
Apr 23, 2024	Canaccord Genuity	Buy	Buy	Hold
Apr 17, 2024	Bank of America Securities	Buy	Buy	Hold
Apr 05, 2024	Needham	Buy	Buy	Hold
Apr 03, 2024	RBC Capital	Buy	Buy	Hold
Apr 03, 2024	Needham	Underperform	Underperform	Hold
Feb 23, 2024	RBC Capital	Buy	Buy	Hold
Jan 18, 2024	RBC Capital	Buy	Buy	Hold
Jan 18, 2024	Needham	Underperform	Underperform	Hold
Jul 06, 2023	Needham	Buy	Buy	Hold
Jun 13, 2022	UBS		Buy	Initialise
Feb 25, 2022	Needham	Buy	Buy	Hold
Feb 17, 2022	Goldman Sachs		Buy	Initialise

Intra-Cellular Therapies's last stock rating was published by Cantor Fitzgerald on Oct 31, 2024. The company gave ITCI a "Overweight" rating, the same as its previous rate.

Intra-Cellular Therapies Financial Forecast

Intra-Cellular Therapies Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	-	-	$126.17M	$110.79M	$94.73M	$87.43M	$71.87M	$55.07M	$34.76M	$25.52M	$21.61M	$19.01M	$15.58M	$12.40M	$7.37M	$1.88M	$882.52K	-	-	-	-	$95.29K	-
Avg Forecast	$266.79M	$234.97M	$215.63M	$197.76M	$194.05M	$172.30M	$157.90M	$141.41M	$135.68M	$119.25M	$106.45M	$92.11M	$87.01M	$65.99M	$49.04M	$33.66M	$25.03M	$22.08M	$19.03M	$16.70M	$11.82M	$5.53M	$2.92M	$1.44M	$12.50K	$14.29K	$12.50K	$6.48B	$110.66K	$6.17B
High Forecast	$274.68M	$241.92M	$222.01M	$200.00M	$194.78M	$172.31M	$157.98M	$142.23M	$139.18M	$123.17M	$109.59M	$94.83M	$89.58M	$65.99M	$49.04M	$33.66M	$25.03M	$22.08M	$19.03M	$16.70M	$11.82M	$5.53M	$2.92M	$1.44M	$12.50K	$14.29K	$12.50K	$7.78B	$132.78K	$7.41B
Low Forecast	$258.41M	$227.59M	$208.86M	$195.33M	$193.19M	$172.30M	$157.82M	$140.58M	$130.25M	$115.50M	$103.10M	$89.22M	$84.27M	$65.99M	$49.04M	$33.66M	$25.03M	$22.08M	$19.03M	$16.70M	$11.82M	$5.53M	$2.92M	$1.44M	$12.50K	$14.29K	$12.50K	$5.18B	$88.52K	$4.94B
# Analysts	3	3	3	5	9	4	4	4	5	11	5	9	5	4	4	7	5	5	10	7	5	6	4	4	4	3	7	9	19	15
Surprise %	-	-	-	-	-	-	-	-	-	1.06%	1.04%	1.03%	1.00%	1.09%	1.12%	1.03%	1.02%	0.98%	1.00%	0.93%	1.05%	1.33%	0.64%	0.61%	-	-	-	-	0.86%	-

Intra-Cellular Therapies's average Quarter revenue forecast for Dec 23 based on 5 analysts is $135.68M, with a low forecast of $130.25M, and a high forecast of $139.18M. ITCI's average Quarter revenue forecast represents a 7.54% increase compared to the company's last Quarter revenue of $126.17M (Sep 23).

Intra-Cellular Therapies EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	3	3	3	5	9	4	4	4	5	11	5	9	5	4	4	7	5	5	10	7	5	6	4	4	4	3	7	9	19	15
EBITDA	-	-	-	-	-	-	-	-	-	$-29.71M	$-47.18M	$-48.39M	$-47.41M	$-55.46M	$-87.92M	$-72.49M	$-85.86M	$-77.19M	$-69.02M	$-53.09M	$-61.21M	$-55.82M	$-64.74M	$-48.94M	$-36.25M	$-39.07M	$-36.59M	$-37.00M	$-27.70M	$-28.45M
Avg Forecast	$-231.69M	$-204.05M	$-187.26M	$-171.74M	$-168.52M	$-149.63M	$-137.12M	$-71.91M	$-117.83M	$-103.56M	$-92.44M	$-76.91M	$-84.72M	$-57.33M	$-42.60M	$-82.26M	$-21.74M	$-19.18M	$-16.54M	$-62.47M	$-10.27M	$-4.80M	$-2.53M	$-57.42M	$-10.86K	$-12.41K	$-46.69M	$-37.56M	$-30.62M	$-33.56M
High Forecast	$-224.41M	$-197.64M	$-181.38M	$-169.63M	$-167.77M	$-149.63M	$-137.05M	$-57.53M	$-113.11M	$-100.30M	$-89.54M	$-61.53M	$-67.78M	$-57.33M	$-42.60M	$-65.81M	$-21.74M	$-19.18M	$-16.54M	$-49.98M	$-10.27M	$-4.80M	$-2.53M	$-45.94M	$-10.86K	$-12.41K	$-37.35M	$-30.05M	$-24.49M	$-26.85M
Low Forecast	$-238.54M	$-210.08M	$-192.80M	$-173.69M	$-169.15M	$-149.63M	$-137.19M	$-86.30M	$-120.86M	$-106.97M	$-95.17M	$-92.30M	$-101.67M	$-57.33M	$-42.60M	$-98.71M	$-21.74M	$-19.18M	$-16.54M	$-74.97M	$-10.27M	$-4.80M	$-2.53M	$-68.91M	$-10.86K	$-12.41K	$-56.03M	$-45.07M	$-36.74M	$-40.27M
Surprise %	-	-	-	-	-	-	-	-	-	0.29%	0.51%	0.63%	0.56%	0.97%	2.06%	0.88%	3.95%	4.02%	4.17%	0.85%	5.96%	11.62%	25.55%	0.85%	3337.99%	3147.95%	0.78%	0.99%	0.90%	0.85%

undefined analysts predict ITCI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Intra-Cellular Therapies's previous annual EBITDA (undefined) of $NaN.

Intra-Cellular Therapies Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	3	3	3	5	9	4	4	4	5	11	5	9	5	4	4	7	5	5	10	7	5	6	4	4	4	3	7	9	19	15
Net Income	-	-	-	-	-	-	-	-	-	$-24.26M	$-42.78M	$-44.05M	$-37.25M	$-53.51M	$-83.96M	$-72.12M	$-85.19M	$-76.91M	$-68.74M	$-52.74M	$-60.70M	$-53.68M	$-61.39M	$-47.41M	$-33.35M	$-37.44M	$-32.98M	$-33.88M	$-26.93M	$-27.19M
Avg Forecast	$23.27M	$4.99M	$-4.53M	$-14.51M	$-7.14M	$-18.96M	$-20.12M	$-72.64M	$-47.69M	$-59.80M	$-62.42M	$-77.69M	$-84.91M	$-84.42M	$-78.81M	$-83.09M	$-104.33M	$-95.99M	$-82.06M	$-62.63M	$-87.70M	$-103.31M	$-94.26M	$-57.61M	$-83.24M	$-86.25M	$-44.45M	$-36.02M	$-30.67M	$-32.84M
High Forecast	$24.16M	$5.18M	$-4.35M	$-11.45M	$31.41M	$-18.18M	$-19.30M	$-58.11M	$-41.19M	$-49.12M	$-59.87M	$-62.15M	$-67.93M	$-84.42M	$-78.81M	$-66.47M	$-104.33M	$-95.99M	$-82.06M	$-50.10M	$-87.70M	$-103.31M	$-94.26M	$-46.09M	$-83.24M	$-86.25M	$-35.56M	$-28.81M	$-24.54M	$-26.27M
Low Forecast	$22.32M	$4.78M	$-4.71M	$-17.56M	$-22.85M	$-19.69M	$-20.89M	$-87.17M	$-55.28M	$-67.28M	$-64.81M	$-93.23M	$-101.90M	$-84.42M	$-78.81M	$-99.71M	$-104.33M	$-95.99M	$-82.06M	$-75.15M	$-87.70M	$-103.31M	$-94.26M	$-69.13M	$-83.24M	$-86.25M	$-53.33M	$-43.22M	$-36.81M	$-39.41M
Surprise %	-	-	-	-	-	-	-	-	-	0.41%	0.69%	0.57%	0.44%	0.63%	1.07%	0.87%	0.82%	0.80%	0.84%	0.84%	0.69%	0.52%	0.65%	0.82%	0.40%	0.43%	0.74%	0.94%	0.88%	0.83%

Intra-Cellular Therapies's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ITCI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Intra-Cellular Therapies SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	3	3	3	5	9	4	4	4	5	11	5	9	5	4	4	7	5	5	10	7	5	6	4	4	4	3	7	9	19	15
SG&A	-	-	-	-	-	-	-	-	-	$105.21M	$101.01M	$98.92M	$94.63M	$88.38M	$100.32M	$75.46M	$79.68M	$70.50M	$69.85M	$52.58M	$58.35M	$52.47M	$41.45M	$34.10M	$15.04M	$15.44M	$11.70M	$6.38M	$6.31M	$5.06M
Avg Forecast	$57.92B	$51.01B	$46.81B	$42.93B	$42.13B	$37.40B	$34.28B	$76.01M	$29.46B	$25.89B	$23.11B	$81.29M	$81.55M	$14.33B	$10.65B	$7.31B	$5.43B	$4.79B	$4.13B	$3.63B	$2.57B	$1.20B	$633.09M	$312.58M	$2.71M	$3.10M	$2.71M	$6.48M	$24.02M	$5.97M
High Forecast	$59.63B	$52.52B	$48.20B	$43.42B	$42.29B	$37.41B	$34.30B	$91.21M	$30.21B	$26.74B	$23.79B	$97.55M	$97.87M	$14.33B	$10.65B	$7.31B	$5.43B	$4.79B	$4.13B	$3.63B	$2.57B	$1.20B	$633.09M	$312.58M	$2.71M	$3.10M	$2.71M	$7.77M	$28.83M	$7.17M
Low Forecast	$56.10B	$49.41B	$45.34B	$42.40B	$41.94B	$37.40B	$34.26B	$60.81M	$28.28B	$25.07B	$22.38B	$65.03M	$65.24M	$14.33B	$10.65B	$7.31B	$5.43B	$4.79B	$4.13B	$3.63B	$2.57B	$1.20B	$633.09M	$312.58M	$2.71M	$3.10M	$2.71M	$5.18M	$19.22M	$4.78M
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	0.00%	1.22%	1.16%	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0.01%	0.02%	0.04%	0.07%	0.11%	5.54%	4.98%	4.31%	0.99%	0.26%	0.85%

Intra-Cellular Therapies's average Quarter SG&A projection for Dec 23 is $29.46B, based on 5 Wall Street analysts, with a range of $28.28B to $30.21B. The forecast indicates a 27897.21% rise compared to ITCI last annual SG&A of $105.21M (Sep 23).

Intra-Cellular Therapies EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	3	3	3	5	9	4	4	4	5	11	5	9	5	4	4	7	5	5	10	7	5	6	4	4	4	3	7	9	19	15
EPS	-	-	-	-	-	-	-	-	-	$-0.25	$-0.00	$-0.46	$-0.39	$-0.57	$-0.89	$-0.78	$-1.05	$-0.95	$-0.85	$-0.65	$-0.76	$-0.77	$-0.92	$-0.73	$-0.60	$-0.68	$-0.60	$-0.62	$-0.62	$-0.63
Avg Forecast	$0.22	$0.05	$-0.04	$-0.14	$-0.07	$-0.18	$-0.19	$-0.32	$-0.45	$-0.57	$-0.59	$-0.61	$-0.59	$-0.81	$-0.76	$-0.92	$-1.01	$-0.93	$-0.79	$-0.79	$-0.85	$-1.00	$-0.91	$-0.93	$-0.80	$-0.83	$-0.87	$-0.67	$-0.82	$-0.92
High Forecast	$0.23	$0.05	$-0.04	$-0.11	$0.30	$-0.17	$-0.18	$-0.30	$-0.39	$-0.46	$-0.57	$-0.58	$-0.57	$-0.81	$-0.76	$-0.92	$-1.01	$-0.93	$-0.79	$-0.79	$-0.85	$-1.00	$-0.91	$-0.93	$-0.80	$-0.83	$-0.87	$-0.54	$-0.66	$-0.74
Low Forecast	$0.21	$0.05	$-0.04	$-0.17	$-0.22	$-0.19	$-0.20	$-0.33	$-0.52	$-0.64	$-0.61	$-0.63	$-0.62	$-0.81	$-0.76	$-0.92	$-1.01	$-0.93	$-0.79	$-0.79	$-0.85	$-1.00	$-0.91	$-0.93	$-0.80	$-0.83	$-0.87	$-0.80	$-0.98	$-1.10
Surprise %	-	-	-	-	-	-	-	-	-	0.44%	0.00%	0.76%	0.66%	0.70%	1.17%	0.85%	1.04%	1.03%	1.07%	0.82%	0.90%	0.77%	1.01%	0.79%	0.75%	0.82%	0.69%	0.93%	0.76%	0.68%

According to undefined Wall Street analysts, Intra-Cellular Therapies's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ITCI previous annual EPS of $NaN (undefined).

Intra-Cellular Therapies Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
IRWD	Ironwood Pharmaceuticals	$3.53	$8.50	140.79%	Buy
DVAX	Dynavax	$12.90	$29.00	124.81%	Buy
AMPH	Amphastar Pharmaceuticals	$40.85	$66.00	61.57%	Buy
CYTH	Cyclo Therapeutics	$0.66	$0.95	43.94%	Buy
AMRX	Amneal Pharmaceuticals	$8.07	$11.50	42.50%	Buy
ANIP	ANI Pharmaceuticals	$55.83	$79.00	41.50%	Buy
COLL	Collegium Pharmaceutical	$30.90	$42.33	36.99%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
PCRX	Pacira BioSciences	$19.83	$23.75	19.77%	Hold
NBIX	Neurocrine Biosciences	$136.69	$156.14	14.23%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy

ITCI Forecast FAQ

Is Intra-Cellular Therapies a good buy?

Yes, according to 9 Wall Street analysts, Intra-Cellular Therapies (ITCI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of ITCI's total ratings.

What is ITCI's price target?

Intra-Cellular Therapies (ITCI) average price target is $93.33 with a range of $79 to $106, implying a 11.84% from its last price of $83.45. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Intra-Cellular Therapies stock go up soon?

According to Wall Street analysts' prediction for ITCI stock, the company can go up by 11.84% (from the last price of $83.45 to the average price target of $93.33), up by 27.02% based on the highest stock price target, and down by -5.33% based on the lowest stock price target.

Can Intra-Cellular Therapies stock reach $130?

ITCI's average twelve months analyst stock price target of $93.33 does not support the claim that Intra-Cellular Therapies can reach $130 in the near future.

What are Intra-Cellular Therapies's analysts' financial forecasts?

Intra-Cellular Therapies's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $665.66M (high $667.31M, low $663.88M), average EBITDA is $-527M (high $-512M, low $-542M), average net income is $-119M (high $-64.183M, low $-151M), average SG&A $113.89B (high $114.08B, low $113.66B), and average EPS is $-0.754 (high $-0.362, low $-0.929). ITCI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $915.16M (high $938.61M, low $890.2M), average EBITDA is $-795M (high $-773M, low $-815M), average net income is $9.22M (high $13.54M, low $4.84M), average SG&A $198.67B (high $203.76B, low $193.25B), and average EPS is $0.0871 (high $0.128, low $0.0457).

Did the ITCI's actual financial results beat the analysts' financial forecasts?

Based on Intra-Cellular Therapies's last annual report (Dec 2022), the company's revenue was $249.13M, beating the average analysts forecast of $235.69M by 5.70%. Apple's EBITDA was $-264M, missing the average prediction of $-267M by -1.23%. The company's net income was $-256M, missing the average estimation of $-331M by -22.64%. Apple's SG&A was $358.78M, missing the average forecast of $32.36B by -98.89%. Lastly, the company's EPS was $-2.72, missing the average prediction of $-3.086 by -11.87%. In terms of the last quarterly report (Sep 2023), Intra-Cellular Therapies's revenue was $126.17M, beating the average analysts' forecast of $119.25M by 5.81%. The company's EBITDA was $-29.713M, missing the average prediction of $-104M by -71.31%. Intra-Cellular Therapies's net income was $-24.258M, missing the average estimation of $-59.801M by -59.44%. The company's SG&A was $105.21M, missing the average forecast of $25.89B by -99.59%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-0.565 by -55.78%